What’s the current market cap for Ocular Therapeutix stock?

Ocular Therapeutix (OCUL) has a market cap of $1.8B as of May 27, 2026.

What is the P/E ratio for Ocular Therapeutix stock?

The price to earnings (P/E) ratio for Ocular Therapeutix (OCUL) stock is 0 as of May 27, 2026.

Does Ocular Therapeutix stock pay dividends?

No, Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders as of May 27, 2026.

When is the next Ocular Therapeutix dividend payment date?

Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders.

What is the beta indicator for Ocular Therapeutix?

Ocular Therapeutix (OCUL) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Ocular Therapeutix stock | $OCUL Share Price

About Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ticker

$OCUL

Sector

Health

Primary listing

NASDAQ

Employees

325

Headquarters

Bedford, United States

Website

www.ocutx.com

OCUL Metrics

BasicAdvanced

$1.8bn

-

-$1.45

0.93

-

What the Analysts think about OCUL

Analyst ratings (Buy, Hold, Sell) for Ocular Therapeutix stock.

Bulls say / Bears say

AXPAXLI (OTX-TKI) secured a major victory in the Phase 3 SOL-1 trial, showing statistically significant superiority to Regeneron’s aflibercept—74.1% vs. 55.8% of patients maintained vision at Week 36 (p = 0.0006)—marking the first time a new mechanism has outperformed an approved anti-VEGF in a wet AMD study aligned with the FDA (Reuters)

With $666.7 million in cash and cash equivalents as of March 31, 2026, Ocular has a secure cash runway into 2028 to support continued advancement of its SOL-1, SOL-R, SOL-X, and HELIOS-3 Phase 3 trials without immediate pressure to raise funds (SEC Form 8-K)

Ocular plans to submit a New Drug Application for AXPAXLI based on positive SOL-1 Week 52 results through the 505(b)(2) pathway, which could shorten the FDA review period by up to two months, and is preparing for commercial launch with an Investor Day on June 17, 2026 (SEC Form 8-K)

Despite positive trial results, DEXTENZA is still Ocular’s only revenue source, with Q1 2026 net product revenue at just $10.8 million, up only 0.8% year-over-year, which highlights weak commercial momentum and a high dependence on one product (SEC Form 8-K)

Ocular’s R&D expenses rose to $66.2 million in the first quarter, up from $42.9 million a year earlier, leading to a net loss of $88.6 million in Q1 2026 and signaling a significant cash burn relative to its modest revenue (SEC Form 8-K)

On March 20, 2026, EyePoint Pharmaceuticals filed a lawsuit accusing Ocular of making false or misleading claims about AXPAXLI, exposing Ocular to legal and reputational risks that could distract management and delay development or commercialization (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

OCUL Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

OCUL Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

OCUL News

AllArticlesVideos

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Reuters·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Ocular Therapeutix

Ticker

Employees

OCUL Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about OCUL

Analyst Ratings

Bulls say / Bears say

OCUL Financial Performance

Income Statement

OCUL Earnings Performance

Earnings per share (EPS)

OCUL News

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Buy $OCUL

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Ocular Therapeutix/$OCUL

About Ocular Therapeutix

Ticker

Employees

OCUL Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about OCUL

Analyst Ratings

Bulls say / Bears say

OCUL Financial Performance

Income Statement

OCUL Earnings Performance

Earnings per share (EPS)

OCUL News

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Buy $OCUL

Upcoming events

No upcoming events

What’s the current market cap for Ocular Therapeutix stock?

What is the P/E ratio for Ocular Therapeutix stock?

Does Ocular Therapeutix stock pay dividends?

When is the next Ocular Therapeutix dividend payment date?

What is the beta indicator for Ocular Therapeutix?

Bulls say / Bears say